<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04070976</url>
  </required_header>
  <id_info>
    <org_study_id>019/036/ICI</org_study_id>
    <nct_id>NCT04070976</nct_id>
  </id_info>
  <brief_title>Chemotherapy and Pelvic Hypofractionated Radiation Followed by Brachytherapy for Cervical Cancer</brief_title>
  <official_title>Phase II Randomized Controlled Trial of Concomitant Chemoradiotherapy With Standard Fractionation Compared to Hypofractionated Concomitant Chemoradiotherapy Followed by Brachytherapy, for Clinical Stage III Cervical Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Cancerología</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Cancerología</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this trial is to assess the safety and response rate to concomitant
      chemotherapy and external hypofractionated radiotherapy followed by brachytherapy in patients
      with clinical stage III cervical cancer. The trial will take place in the National Cancer
      Institute (INCan). Patients will be randomized into two groups: chemotherapy with external
      standard fractionated radiotherapy (45 Gy in 25 fractions) followed by brachytherapy or
      chemotherapy with external hypofractionated radiotherapy (37.5 Gy in 15 fractions) followed
      by brachytherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint will be to assess the safety and efficacy to concomitant
      chemoradiotherapy followed by brachytherapy in cervical cancer clinical stage III. Secondary
      endpoints comprises security profile, survival rates, quality of life and related costs.

      The data obtained by this protocol will allow to determine the effect of hypofractionated
      radiation therapy and its possible adverse effects. Side effects will be classified according
      to version 4.03 of CTCAE guidelines. The highest CTCAE grade will be obtained for each type
      of event, for each patient and the Radiation Therapy Oncology Group (RTOG) scale will be
      applied to evaluate the events related to conventional and hypofractionated radiotherapy, as
      well as brachytherapy.

      Quality of life (QOL) will be evaluated using EORTC QLQ-CX24 and EORTC QLQ-C30, both have
      been validated and available in Mexican Spanish.

      Direct and indirect expenses related to the treatment will be evaluated based on the
      treatment costs stipulate by the institution and the information obtained by the social
      workers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute and late toxicity</measure>
    <time_frame>2 years</time_frame>
    <description>Number of Participants With Treatment-Related Adverse Events as Assessed by RTOG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment efficacy</measure>
    <time_frame>2 years</time_frame>
    <description>Hypofractionated radiotherapy is similar in toxicity and disease control compared to standard external beam treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival rate</measure>
    <time_frame>2 years</time_frame>
    <description>Number of participants dead of disease at two years according to kaplan-meyer analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>2 years</time_frame>
    <description>Number ofpParticipants dead at two years according to kaplan-meyer analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction assessed by EORTC</measure>
    <time_frame>2 years</time_frame>
    <description>Assessed individual's overall satisfaction with life and general sense of personal well-being by ERTC QLQ-C30 and QLQ-CX24 questionaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct and indirect costs related to treatment.</measure>
    <time_frame>2 years</time_frame>
    <description>Direct costs related to the treatment. Indirect costs related to the treatment (transport, housing, food, etc.)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cisplatin 40mg/m2 weekly and concomitant pelvic radiotherapy (45 Gray/25 fractions) followed by brachytherapy 28Gray at point A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin 40mg/m2 weekly and hypofractionated concomitant external radiotherapy (37,50 Gray/15 fractions) followed by brachytherapy 28 Gray at point A.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated therapy</intervention_name>
    <description>All patients will be treated with an external beam of 37.5 Gray in 15 fractions (2.5 Gray / fraction). They will be treated once a day, 5 days a week. If photon energy 6 MV or 10 MV is used, the patient should be treated with a 4-field technique using the anterior/posterior field and 2 lateral fields. The specification of the dose is in terms of a dose to a point at or near the center of the target volume. For all field dispositions, the dose specification point is the common isocenter of all beams.</description>
    <arm_group_label>Experimental treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard therapy</intervention_name>
    <description>All patients will be treated with external beam radiotherapy with 50 Gray in 25 fractions (1.8-2 Gray / fraction). They will be treated once a day, 5 days a week. If photon energy 6 MV or 10 MV is used, the patient should be treated with a 4-field technique using anterior/posterior fields and 2 lateral fields. The specification of the dose is in terms of a dose to a point at or near the center of the target volume. For all field dispositions, the dose specification point is the common isocenter of all beams.</description>
    <arm_group_label>Standard treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women over 18 years old

          -  Cervical Cancer at IIIA, IIIB y IIIC1 FIGO´s clinical stages

          -  Histology: squamous, adenosquamous or adenocarcinoma

          -  No previous treatment

          -  No distance metastases, discard by Positron Emission Tomography (PET)/CT

          -  Functional State ECOG (Eastern Cooperative Oncology Group) 0-2

          -  Complete Blood count obtained at least 14 days before admission to the study with
             adequate bone marrow function defined as:

          -  Absolute neutrophil count ≥ 1,500 cell/mm3

          -  Platelets ≥ 100,000 cell/mm3

          -  Hemoglobin ≥ 10.0 g/dl

          -  Leukocyte count ≥ 4000 cell/mm3

          -  Adequate Renal Function defined as:

          -  Serum Creatinine ≤ 1.5 mg/dl within 14 days before admission to the study

          -  Patients with HIV infection (human immunodeficiency virus) must have a CD4 cell count
             ≥ 350 cells / mm3 measured within 14 days prior to study entry (no HIV test is
             required)

          -  The patient must understand the protocol and provide the specific informed consent of
             the study before admission

          -  Negative pregnancy test

        Exclusion Criteria:

          -  Patients who had chemotherapeutic, surgical and/or radiotherapy treatment for female
             reproductive tract pathologies

          -  Previous invasive neoplasia (except non-melanoma skin cancer) unless there is complete
             remission of the disease of 3 years minimum (For example, breast cancer or oral cavity
             cancer)

          -  Previous systemic chemotherapy for current cervical cancer, take into account that
             prior chemotherapy for a different cancer is accepted, as long as they have been at
             least 3 years

          -  Severe active or non-controlled co-morbidities, defined as:

          -  Unstable angina and/or congestive heart failure that required hospitalization in the
             last 6 months.

          -  Transmural myocardial infarction in the last 6 months.

          -  Acute bacterial or fungal infection requiring intravenous antibiotics at the beginning
             of the study.

          -  Chronic obstructive pulmonary disease exacerbation or another respiratory disease that
             requires hospitalization or that contraindicates the trial therapy at the time of
             admission.

          -  Crohn's disease or ulcerative colitis.

          -  Prior allergic reaction to cisplatin or other drugs based on platinum.

          -  Other factors that contraindicate experimental therapy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David F Cantú-deLeón</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Cancerología</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David F Cantú-de León, Md, MSc. PhD</last_name>
    <phone>+525537093156</phone>
    <email>dfcantu@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lenny N Gallardo-Alvarado, MD, MSc</last_name>
    <phone>+52553702118</phone>
    <email>dra.ngallardo@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>David Cantu de Leon</name>
      <address>
        <city>Mexico City</city>
        <state>Tlalpan</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David F Cantu-de Leon, MD. Msc. Phd</last_name>
      <phone>+5215537093116</phone>
      <email>dfcantu@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer</url>
    <description>Human papillomavirus (HPV) and cervical cancer [Internet]</description>
  </link>
  <reference>
    <citation>Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.</citation>
    <PMID>25220842</PMID>
  </reference>
  <reference>
    <citation>Gosvig CF, Huusom LD, Andersen KK, Duun-Henriksen AK, Frederiksen K, Iftner A, Svare E, Iftner T, Kjaer SK. Long-term follow-up of the risk for cervical intraepithelial neoplasia grade 2 or worse in HPV-negative women after conization. Int J Cancer. 2015 Dec 15;137(12):2927-33. doi: 10.1002/ijc.29673. Epub 2015 Jul 25.</citation>
    <PMID>26139420</PMID>
  </reference>
  <reference>
    <citation>Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM, Mutch DG. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999 Apr 15;340(15):1137-43.</citation>
    <PMID>10202164</PMID>
  </reference>
  <reference>
    <citation>Carlson RW, Scavone JL, Koh WJ, McClure JS, Greer BE, Kumar R, McMillian NR, Anderson BO. NCCN Framework for Resource Stratification: A Framework for Providing and Improving Global Quality Oncology Care. J Natl Compr Canc Netw. 2016 Aug;14(8):961-9.</citation>
    <PMID>27496112</PMID>
  </reference>
  <reference>
    <citation>Robin TP, Amini A, Schefter TE, Behbakht K, Fisher CM. Disparities in standard of care treatment and associated survival decrement in patients with locally advanced cervical cancer. Gynecol Oncol. 2016 Nov;143(2):319-325. doi: 10.1016/j.ygyno.2016.09.009. Epub 2016 Sep 16.</citation>
    <PMID>27640961</PMID>
  </reference>
  <reference>
    <citation>Greenup RA, Blitzblau RC, Houck KL, Sosa JA, Horton J, Peppercorn JM, Taghian AG, Smith BL, Hwang ES. Cost Implications of an Evidence-Based Approach to Radiation Treatment After Lumpectomy for Early-Stage Breast Cancer. J Oncol Pract. 2017 Apr;13(4):e283-e290. doi: 10.1200/JOP.2016.016683. Epub 2017 Mar 14.</citation>
    <PMID>28291382</PMID>
  </reference>
  <reference>
    <citation>Muckaden MA, Budrukkar AN, Tongaonkar HB, Dinshaw KA. Hypofractionated radiotherapy in carcinoma cervix IIIB: Tata Memorial Hospital experience. Indian J Cancer. 2002 Oct-Dec;39(4):127-34.</citation>
    <PMID>12928570</PMID>
  </reference>
  <reference>
    <citation>Zhang H, Wang JZ, Mayr N, Kong X, Yuan J, Gupta N, Lo S, Grecula J, Montebello J, Martin D, Yuh W. Fractionated grid therapy in treating cervical cancers: conventional fractionation or hypofractionation? Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):280-8. Epub 2007 Oct 29.</citation>
    <PMID>17967516</PMID>
  </reference>
  <reference>
    <citation>Hoffman KE, Voong KR, Pugh TJ, Skinner H, Levy LB, Takiar V, Choi S, Du W, Frank SJ, Johnson J, Kanke J, Kudchadker RJ, Lee AK, Mahmood U, McGuire SE, Kuban DA. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1074-84. doi: 10.1016/j.ijrobp.2014.01.015.</citation>
    <PMID>24661661</PMID>
  </reference>
  <reference>
    <citation>Antoni S, Soerjomataram I, Møller B, Bray F, Ferlay J. An assessment of GLOBOCAN methods for deriving national estimates of cancer incidence. Bull World Health Organ. 2016 Mar 1;94(3):174-84. doi: 10.2471/BLT.15.164384. Epub 2016 Jan 28.</citation>
    <PMID>26966328</PMID>
  </reference>
  <reference>
    <citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.</citation>
    <PMID>30207593</PMID>
  </reference>
  <reference>
    <citation>Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019 Apr 15;144(8):1941-1953. doi: 10.1002/ijc.31937. Epub 2018 Dec 6.</citation>
    <PMID>30350310</PMID>
  </reference>
  <reference>
    <citation>Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:22-36. doi: 10.1002/ijgo.12611.</citation>
    <PMID>30306584</PMID>
  </reference>
  <reference>
    <citation>FIGO Committee on Gynecologic Oncology. FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. Int J Gynaecol Obstet. 2014 May;125(2):97-8. doi: 10.1016/j.ijgo.2014.02.003. Epub 2014 Feb 22.</citation>
    <PMID>24630859</PMID>
  </reference>
  <reference>
    <citation>Chuang LT, Temin S, Camacho R, Dueñas-Gonzalez A, Feldman S, Gultekin M, Gupta V, Horton S, Jacob G, Kidd EA, Lishimpi K, Nakisige C, Nam JH, Ngan HYS, Small W, Thomas G, Berek JS. Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline. J Glob Oncol. 2016 May 25;2(5):311-340. doi: 10.1200/JGO.2016.003954. eCollection 2016 Oct.</citation>
    <PMID>28717717</PMID>
  </reference>
  <reference>
    <citation>Leath CA 3rd, Monk BJ. Twenty-first century cervical cancer management: A historical perspective of the gynecologic oncology group/NRG oncology over the past twenty years. Gynecol Oncol. 2018 Sep;150(3):391-397. doi: 10.1016/j.ygyno.2018.06.023. Epub 2018 Jun 27. Review.</citation>
    <PMID>29954593</PMID>
  </reference>
  <reference>
    <citation>Kirwan JM, Symonds P, Green JA, Tierney J, Collingwood M, Williams CJ. A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol. 2003 Sep;68(3):217-26. Review.</citation>
    <PMID>13129628</PMID>
  </reference>
  <reference>
    <citation>Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Clark R, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Wyse E, Yashar CM, McMillian NR, Scavone JL. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 Jan;17(1):64-84. doi: 10.6004/jnccn.2019.0001.</citation>
    <PMID>30659131</PMID>
  </reference>
  <reference>
    <citation>Das S, Subhashini J, Rami Reddy JK, KantiPal S, Isiah R, Oommen R. Low-dose fractionated radiation and chemotherapy prior to definitive chemoradiation in locally advanced carcinoma of the uterine cervix: Results of a prospective phase II clinical trial. Gynecol Oncol. 2015 Aug;138(2):292-8. doi: 10.1016/j.ygyno.2015.05.020. Epub 2015 May 23.</citation>
    <PMID>26013695</PMID>
  </reference>
  <reference>
    <citation>Dueñas-González A, Zarbá JJ, Patel F, Alcedo JC, Beslija S, Casanova L, Pattaranutaporn P, Hameed S, Blair JM, Barraclough H, Orlando M. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol. 2011 May 1;29(13):1678-85. doi: 10.1200/JCO.2009.25.9663. Epub 2011 Mar 28.</citation>
    <PMID>21444871</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 22, 2019</study_first_submitted>
  <study_first_submitted_qc>August 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>August 26, 2019</last_update_submitted>
  <last_update_submitted_qc>August 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Cancerología</investigator_affiliation>
    <investigator_full_name>David Cantu</investigator_full_name>
    <investigator_title>Chief of clinical trials department</investigator_title>
  </responsible_party>
  <keyword>hypofractionated radiotherapy</keyword>
  <keyword>Brachytherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>2 years</ipd_time_frame>
    <ipd_access_criteria>the data will be shared with scientific and academic institutions or research groups that study the same topic and with the regulatory and ethical authorities that require it, to ensure the quality and accuracy of the data.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

